Check­mate Phar­ma­ceu­ti­cals brings two new ex­ecs on board; Take­da sheds 30 drugs, gains $200M in Aci­no deal

→ Amid a $22 mil­lion fi­nanc­ing round led by Decheng Cap­i­tal last year, Check­mate Phar­ma­ceu­ti­cals CEO Art Krieg an­nounced that he was turn­ing in his tile to Bar­ry Labinger and, in­stead, mov­ing to a CSO role with­in the com­pa­ny. Now, the Cam­bridge, Mass­a­chu­setts-based com­pa­ny wel­comes two new ex­ecs to the team: James Wooldridge as CMO and Steven Ham­burg­er as vice pres­i­dent of reg­u­la­to­ry af­fairs.

“In the past year, we have made tremen­dous progress in ad­vanc­ing the de­vel­op­ment of our lead com­pound, CMP-001, that is cur­rent­ly in clin­i­cal tri­als in com­bi­na­tion with an­ti-PD-1/L1 an­ti­bod­ies for mul­ti­ple sol­id tu­mor types,” said Labinger.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER